The Chemours Company (NYSE:CC) Shares Acquired by Intech Investment Management LLC

Intech Investment Management LLC raised its position in The Chemours Company (NYSE:CC - Free Report) by 639.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 135,790 shares of the specialty chemicals company's stock after acquiring an additional 117,415 shares during the quarter. Intech Investment Management LLC owned 0.09% of Chemours worth $2,295,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. Corient Private Wealth LLC increased its stake in Chemours by 4.7% during the 4th quarter. Corient Private Wealth LLC now owns 13,428 shares of the specialty chemicals company's stock worth $227,000 after buying an additional 604 shares during the period. KBC Group NV increased its position in shares of Chemours by 19.5% during the third quarter. KBC Group NV now owns 4,468 shares of the specialty chemicals company's stock worth $91,000 after acquiring an additional 728 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Chemours by 99.7% in the fourth quarter. GAMMA Investing LLC now owns 1,532 shares of the specialty chemicals company's stock worth $26,000 after acquiring an additional 765 shares in the last quarter. ARGA Investment Management LP boosted its holdings in Chemours by 0.7% in the fourth quarter. ARGA Investment Management LP now owns 148,614 shares of the specialty chemicals company's stock valued at $2,512,000 after purchasing an additional 1,032 shares during the last quarter. Finally, Heritage Investors Management Corp boosted its holdings in Chemours by 1.1% in the fourth quarter. Heritage Investors Management Corp now owns 105,322 shares of the specialty chemicals company's stock valued at $1,780,000 after purchasing an additional 1,174 shares during the last quarter. Hedge funds and other institutional investors own 76.26% of the company's stock.

Remove Ads

Chemours Stock Performance

Shares of NYSE CC traded down $0.29 during mid-day trading on Tuesday, hitting $14.16. The company had a trading volume of 1,792,271 shares, compared to its average volume of 1,674,038. The Chemours Company has a 12 month low of $13.09 and a 12 month high of $29.21. The stock has a market cap of $2.12 billion, a price-to-earnings ratio of 24.84 and a beta of 2.00. The company has a debt-to-equity ratio of 6.70, a current ratio of 1.68 and a quick ratio of 0.92. The firm's 50 day simple moving average is $16.81 and its two-hundred day simple moving average is $18.30.

Chemours (NYSE:CC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 18th. The specialty chemicals company reported $0.11 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $0.01. Chemours had a net margin of 1.51% and a return on equity of 26.54%. The company had revenue of $1.36 billion during the quarter, compared to the consensus estimate of $1.37 billion. As a group, equities research analysts forecast that The Chemours Company will post 2.03 earnings per share for the current year.

Chemours Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, March 14th. Investors of record on Friday, February 28th were issued a $0.25 dividend. This represents a $1.00 dividend on an annualized basis and a yield of 7.06%. The ex-dividend date of this dividend was Friday, February 28th. Chemours's dividend payout ratio (DPR) is 175.44%.

Analysts Set New Price Targets

Several research firms have recently commented on CC. Truist Financial began coverage on Chemours in a research note on Tuesday, January 28th. They set a "buy" rating and a $27.00 target price for the company. The Goldman Sachs Group reduced their price objective on shares of Chemours from $24.00 to $21.00 and set a "neutral" rating on the stock in a research note on Tuesday, January 7th. Morgan Stanley dropped their target price on shares of Chemours from $25.00 to $22.00 and set an "equal weight" rating for the company in a research report on Monday, January 13th. BMO Capital Markets reduced their price target on shares of Chemours from $34.00 to $27.00 and set an "outperform" rating on the stock in a research report on Wednesday, February 19th. Finally, Royal Bank of Canada reissued an "outperform" rating and issued a $25.00 price objective on shares of Chemours in a report on Thursday, December 12th. Five investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Hold" and an average target price of $23.11.

Chemours Profile

The Chemours Company provides performance chemicals in North America, the Asia Pacific, Europe, the Middle East, Africa, and Latin America. It operates through three segments: Titanium Technologies, Thermal & Specialized Solutions, and Advanced Performance Materials. The Titanium Technologies segment provides TiO2 pigment under the Ti-Pure brand for delivering whiteness, brightness, opacity, durability, efficiency, and protection in various of applications, such as architectural and industrial coatings, flexible and rigid plastic packaging, polyvinylchloride, laminate papers used for furniture and building materials, coated paper, and coated paperboard used for packaging.